Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used increasingly as an anticoagulant during continuous renal replacement therapy (CRRT). However, there, are limited data from randomized studies on NM use in patients with a bleeding tendency. This prospective study evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Ji-Young, Kang, Yun-Jeong, Jang, Hye Min, Jung, Hee-Yeon, Cho, Jang-Hee, Park, Sun-Hee, Kim, Yong-Lim, Kim, Chan-Duck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291631/
https://www.ncbi.nlm.nih.gov/pubmed/26717390
http://dx.doi.org/10.1097/MD.0000000000002392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291631/
https://www.ncbi.nlm.nih.gov/pubmed/26717390
http://dx.doi.org/10.1097/MD.0000000000002392

Ejemplares similares